Search Results | Blood | American Society of Hematology

1-20 of 45

2 3

Sort by

Sort Order Select

Journal Articles

Prediction of Graft-Versus-Host Disease in Recipients of Single Mismatched Unrelated Hematopoietic Cell Transplantation Donor Using a Highly Multiplexed Proteomic Assay, MHC-Pepseq

Karamjeet S. Sandhu, Ketevan Gendzekhadze, Dongyun Yang, Ryotaro Nakamura, Sally Mokhtari, Monzr M. Al Malki, Haris Ali, Amandeep Salhotra, Stephen J Forman, Medhat Askar, John Altin

Blood (2021) 138 (Supplement 1): 1808.

DOI: https://doi.org/10.1182/blood-2021-153597

Published: 2021

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL

Blood (2021) 138 (Supplement 1): 3955.

DOI: https://doi.org/10.1182/blood-2021-153125

Published: 2021

Journal Articles

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2021) 138 (Supplement 1): 3647.

DOI: https://doi.org/10.1182/blood-2021-148668

Published: 2021

Journal Articles

Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias

Brian Ball, Shukaib Arslan, Paul Koller, Joyce Murata-Collins, Michelle Afkhami, Raju Pillai, Karl Gaal, Amandeep Salhotra, Monzr M. Al Malki, Ahmed Aribi, Haris Ali, Salman Otoukesh, Idoroenyi Amanam, Ryotaro Nakamura, Eileen P. Smith, Forrest Stewart, Guido Marcucci, Vinod A. Pullarkat, Ibrahim Aldoss

Blood (2021) 138 (Supplement 1): 3430.

DOI: https://doi.org/10.1182/blood-2021-148670

Published: 2021

Journal Articles

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Abdulraheem Yacoub, Vikas Gupta, Sangmin Lee, Gary J. Schiller, James M. Foran, Ayalew Tefferi, Christopher L Brooks, Guillermo Garcia-Manero, Tariq I. Mughal, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 538.

DOI: https://doi.org/10.1182/blood-2021-147827

Published: 2021

Journal Articles

Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 2318.

DOI: https://doi.org/10.1182/blood-2021-145344

Published: 2021

Journal Articles

Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience

Blood (2021) 138 (Supplement 1): 3037.

DOI: https://doi.org/10.1182/blood-2021-154187

Published: 2021

Journal Articles

A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation

Blood (2021) 138 (Supplement 1): 334.

DOI: https://doi.org/10.1182/blood-2021-153821

Published: 2021

Journal Articles

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

Abdulraheem Yacoub, Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Vikas Gupta, Sangmin Lee, Gary J. Schiller, Minakshi S. Taparia, Animesh Pardanani, Ayalew Tefferi, Srdan Verstovsek, Joseph D. Khoury, Christopher L Brooks, Tariq I. Mughal, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 140.

DOI: https://doi.org/10.1182/blood-2021-145276

Published: 2021

Journal Articles

Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis

Blood (2020) 136 (Supplement 1): 21–22.

DOI: https://doi.org/10.1182/blood-2020-139993

Published: 2020

Journal Articles

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Parameswaran Hari, MD MRCP, Haris Ali, MD, Yi-Bin Chen, MD, Salman Fazal, MD, Tara K. Gregory, MD, Sarah M. Anand, MD, Ahmad Naim, MD, Dilan Paranagama, PhD, Valkal Bhatt, PharmD, Amy Blithe, RD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

DOI: https://doi.org/10.1182/blood-2020-140541

Published: 2020

Journal Articles

Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)

Blood (2020) 136 (Supplement 1): 37–38.

DOI: https://doi.org/10.1182/blood-2020-140538

Published: 2020

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)

Blood (2020) 136 (Supplement 1): 41–42.

DOI: https://doi.org/10.1182/blood-2020-141469

Published: 2020

Journal Articles

Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial

Monzr M. Al Malki, MD, Ni-Chun Tsai, MS, Joycelynne Palmer, PhD, Saloomeh Mokhtari, Thai Cao, MD, Haris Ali, MD, Amandeep Salhotra, MD, Shukaib Arslan, MD, Ibrahim Aldoss, MD, Nicole Karras, MD, Haris M. Ali, MD, Haris Ali, MD, Anthony S. Stein, MD, David S Snyder, MD, Guido Marcucci, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD

Blood (2020) 136 (Supplement 1): 49–50.

DOI: https://doi.org/10.1182/blood-2020-142807

Published: 2020

Journal Articles

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

Naveen Pemmaraju, MD, Vikas Gupta, MD FRCP, FRCPath, Haris Ali, MD, Abdulraheem Yacoub, MD, Eunice S. Wang, MD, Sangmin Lee, MD, Gary J. Schiller, MD, Christopher Brooks, PhD, Nicole Rupprecht, MS, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Moshe Talpaz, MD, Minakshi S. Taparia, MBBS, Tariq I. Mughal, MD FRCP, Srdan Verstovsek, MD PhD, Joseph D. Khoury, MD, Mrinal M. Patnaik, MDMBBS

Blood (2020) 136 (Supplement 1): 39–40.

DOI: https://doi.org/10.1182/blood-2020-137572

Published: 2020

Journal Articles

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Salman Otoukesh, MD, Hany Elmariah, MDMS, Dongyun Yang, PhD, Sally Mokhtari, PhD, Madiha Siraj, Haris Ali, MD, Krishnakar Mogili, Shukaib Arslan, MD, Taiga Nishihori, MD, Chatchada Karanes, MD, Joseph Pidala, MD, Ryotaro Nakamura, MD, Claudio Anasetti, MD, Stephen J. Forman, MD, Monzr M. Al Malki, MD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 10–11.

DOI: https://doi.org/10.1182/blood-2020-143166

Published: 2020

Journal Articles

Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases

Nicole Karras, MD, Ni-Chun Tsai, MS, Ahmed Tahoun, MD, Saloomeh Mokhtari, Haris Ali, MD, Shukaib Arslan, MD, Anna B Pawlowska, MD, Chatchada Karanes, Joseph Rosenthal, MD MS, David S Snyder, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD, Monzr M. Al Malki, MD

Blood (2020) 136 (Supplement 1): 5–6.

DOI: https://doi.org/10.1182/blood-2020-141334

Published: 2020

Journal Articles

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Stephen T. Oh, MD, Jason Gotlib, MD MS, Sanjay Mohan, MD MSCI, Haris Ali, MD, Ekatherine Asatiani, MD, Francis Seguy, Feng Zhou, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 3.

DOI: https://doi.org/10.1182/blood-2020-134574

Published: 2020

Journal Articles

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury

Blood (2020) 135 (20): 1739–1749.

DOI: https://doi.org/10.1182/blood.2020004823

Published: 2020

Includes: Supplemental data

Journal Articles

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

Janny M. Yao, PharmD, Dongyun Yang, PhD, Saloomeh Mokhtari, Amandeep Salhotra, MD, Haris Ali, MD, Shukaib Arslan, MD, Salman Otoukesh, MD, Ibrahim Aldoss, MD, Karamjeet S. Sandhu, MD, Anthony Stein, MD, David Snyder, MD, Vinod A. Pullarkat, MD, Guido Marcucci, MD, Stephen J Forman, MD, Ryotaro Nakamura, MD, Monzr M. Al Malki, MD

Blood (2019) 134 (Supplement_1): 4518.

DOI: https://doi.org/10.1182/blood-2019-129221

Published: 2019

2 3

NARROW

Prediction of Graft-Versus-Host Disease in Recipients of Single Mismatched Unrelated Hematopoietic Cell Transplantation Donor Using a Highly Multiplexed Proteomic Assay, MHC-Pepseq

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies

Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience

A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)

Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only